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PERSPECTIVE
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The Hippo pathway coordinates organ size and cell proliferation. The retinoblastoma family of proteins regulates
progression through the G0/G1 phase of the cell cycle.
Disruption of either pathway contributes to cancer formation. Three recent studies in Genes & Development
reveal how cellular proliferation is coordinated between
these pathways. Here we discuss the implications of these
studies and the new questions that they raise.

The regulation of cellular proliferation is critical to the
development of most tissues and organs. At its most basic
level, control of cell cycle exit allows for precise regulation of organ size, as cell numbers are one of its primary
determinants. Perhaps more importantly, careful control
of cell proliferation during differentiation allows specialized cells to make heterotypic interactions with appropriate neighbors, rather than inappropriate or homotypic
interactions with adjacent cells that arise from aberrant
cycling. In short, the intricate organization of specialized
cells during tissue morphogenesis is highly dependent on
the ability of its constituent cells to read cell cycle exit
cues.
Cancer is often summarized as a disease of inappropriate cell division. The most fundamental characteristics
of cancer cells, called the ‘‘hallmarks’’ of cancer, are intimately related to a cell’s intrinsic ability to control proliferation (Hanahan and Weinberg 2011). Just as the response
to regulatory signals that trigger cell cycle exit is essential
in development, the loss of responsiveness to these signals
allows quiescent or differentiated cells to revert to a more
proliferative state and contribute to tumor development.
The balance between signals that induce proliferation
or suppress it controls the cell cycle. Our knowledge of
these signals and the molecular pathways that transmit
them are only now being revealed. Two proliferative
control pathways that are the focus of recent studies in
Genes & Development from the Frolov (Nicolay et al.
2011), Dyson (Tschöp et al. 2011), and DeCaprio (Litovchick
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et al. 2011) laboratories are the Retinoblastoma (RB)
pathway and the Hippo pathway. Both pathways are well
known to regulate proliferation in development, and
mutations that affect their integrity contribute to cancer
(Classon and Harlow 2002; Pan 2010). In most cases
where these pathways have been investigated in experimental paradigms of development or disease, their roles
are readily detectable. For this reason, a broad question of
interest in understanding cell cycle regulation is whether
these distinctive proliferative control pathways coordinate their activities and, if so, how this is accomplished.
Insight into how separate pathways cooperate in cell cycle
decisions in G1 is essential to truly understand the control
of proliferation in multicellular organisms.

The RB pathway in proliferative control and cancer
E2F transcription factors were some of the earliest pRB
(Retinoblastoma protein)-interacting proteins to be discovered. Ectopic expression of E2Fs induces cell cycle
advancement from G1 to S phase, and expression of pRB
can block this effect, thus offering a simple binary switch
mechanism that can inhibit cell proliferation (Dyson
1998). In G1, pRB binds and inhibits E2Fs. Upon mitogenic signaling, cyclin-dependent kinases phosphorylate
and inactivate pRB, releasing E2Fs to transcribe cell cycle
target genes such as Cyclin E and Mcm3 that induce
progression into S phase (Fig. 1A). While mutation of the
human RB1 gene is the underlying cause of retinoblastoma, and disruption of other components in its regulatory
pathway is a requirement in cancer (Sherr and McCormick
2002), the loss of function of the mouse Rb1 gene reveals a
less than essential role in proliferative control in development. When Rb1 is deleted in the embryo proper, many
tissues and organs develop normally and exit the cell cycle
appropriately (Wu et al. 2003). Furthermore, chimeric mice
composed of a mixture of wild-type and Rb1 knockout
cells revealed that pRB-deficient cells can contribute to
most tissues and organs. Surprisingly, this results in only
mild hyperplasia, and this is observed in only a few developmental contexts (Williams et al. 1994). Conversely,
deletion of Rb1 along with its two related family members,
p107 and p130, results in early embryonic lethality and
massively deregulated proliferation. In only a few instances do these triple-knockout cells display any ability
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between the respective roles for pRB, p107, and p130 in
cell cycle control.
The identification and characterization of DP, RB, E2F,
and MuvB (DREAM) complexes is of great importance
for understanding the biology of RB family proteins. The
Caenorhabditis elegans Lin35 gene resembles human
RB1 and functions in cooperation with E2F-like genes
as well as others in the synMuvB complementation group,
such as Lin9, Lin37, Lin52, and Lin55 (van den Heuvel and
Dyson 2008). The Drosophila Rbf, E2f, and Myb (dREAM)
complex was identified through biochemical purification
and also contains fruit fly orthologs of the synMuvB
components LIN9, LIN37, LIN52, LIN54, and RBBP4
(Korenjak et al. 2004; Lewis et al. 2004). Last, the orthologous human DREAM complex was copurified with p130
(Litovchick et al. 2007). Intriguingly, analysis of DREAM
association with mammalian pocket proteins demonstrated that it is found exclusively with p130, and only
under conditions of p130 loss did it associate with p107
(Litovchick et al. 2007). This suggests that DREAMmediated repression of E2F transcription is specific for
p130 and mechanistically distinct from other RB family
members. To emphasize that DREAM contains p130 in
our discussion of its function, we refer to it as p130–
DREAM throughout this perspective. The unique inclusion of p130 in DREAM raises the question of whether it
can be regulated separately from other pocket protein–
E2F complexes in cell cycle control.
Figure 1. Conservation of the RB and Hippo signaling pathways
in humans and fruit flies. (A) Illustration of the RB pathway from
cyclin-dependent kinases to RB family proteins and E2Fs. The
names of family members from Drosophila melanogaster and
Homo sapiens are indicated. Note that RB family proteins recruit
corepressor complexes to E2F promoters using their pocket
domain. In the case of p130 (humans) and Rbf2 (fruit fly), the
corepressor includes the MuvB core components that assemble
into the DREAM and dREAM complexes, respectively. (B)
Components of the Hippo pathway are similarly diagrammed,
with the names of fruit fly and human counterparts included.

to control the cell cycle (Wirt et al. 2010). The concept of
a shared role for RB family proteins in proliferative
control is of great importance, but has also been a key
impediment to our understanding of how G1-to-S-phase
progression is regulated.
All RB family proteins possess the growth-suppressing
pocket domain and can bind to E2F transcription factors
in order to inhibit transcription of cell cycle genes (Dyson
1998). However, the expression pattern of these proteins
is different in that p130 is the most abundant in quiescent
or differentiated cells and p107 predominates in proliferating cells. The expression of pRB is less dynamic, as it
displays a mild elevation of expression during proliferation.
Remarkably, deletion of any one member of the family
results in up-regulation of the others. In particular, loss of
p130 leads to increased expression of p107 in quiescence,
even though its expression is normally quite low at this
stage of the cell cycle (Hurford et al. 1997). For these reasons, it has been challenging to delineate boundaries
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The role of Hippo in proliferation and development
The Hippo pathway has emerged recently as a critical
regulator of proliferation in development. It was discovered largely through genetic screens for overproliferation
of cells in developing Drosophila embryos (Zhao et al.
2010). The Hippo pathway is an evolutionarily conserved
signaling cascade that senses cell density and in turn
can suppress proliferation (Fig. 1B). In this way, loss of
function of this pathway leads to the appearance of hyperplastic tissue and dramatically enlarged organs (Pan
2010). In transgenic and knockout mice, these overgrowth
phenotypes cause a strong predisposition to cancer, although naturally occurring mutations of Hippo components are relatively rare in human cancer (Pan 2010).
The extracellular origin of signals that control the
activity of the Hippo pathway is largely unknown. The
first transmembrane protein discovered to exert influence
on Hippo is encoded by the Drosophila fat gene (Grusche
et al. 2010). How Fat signals, and the immediate downstream targets that it requires for activating Hippo, is an
area of intensive investigation. Three components that
are downstream from Fat include Expanded (ex), Merlin
(mer), and Kibra (kb). However, it is not clear how they
communicate with Fat or how they signal to the next
component downstream, Hippo. The hippo gene encodes
a kinase (abbreviated as hpo; MST1/2 in mammals) that
phosphorylates and activates the Warts kinase (wts;
LATS1/2 in mammals), which in turn phosphorylates
the transcriptional cofactor Yorkie (yki; YAP/TAZ in
mammals). In the absence of phosphorylation, Yorkie
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translocates to the nucleus, where it cooperates with
DNA-binding factors such as Scalloped (sd; TEAD in
mammals) to induce transcription of genes that advance
the cell cycle (Pan 2010). In this way, signals that activate
the Hippo pathway suppress Yorkie-dependent transcription and inhibit proliferation. In contrast, mutations that
inactivate the negative regulation of Yorkie cause dramatic overgrowth phenotypes in many tissues and organs
in fruit flies and mice alike. The extent of the overgrowth
phenotype has been an important guiding principle in
Hippo signaling. Components such as expanded and
merlin are thought to act in parallel because individual
mutation of these genes causes relatively mild overgrowth
phenotypes. However, fruit flies bearing mutations in both
genes appear more comparable with the single-mutation
phenotypes of core components such as warts or hippo
(Zhao et al. 2010). Transgenic expression of Yorkie also
serves to model deregulation of the pathway, as this
recapitulates the overgrowth phenotype observed from
loss of hippo or warts. Taken together, these data suggest
that Yorkie is the primary target of growth regulation by
the Hippo pathway, and this has led to a focused search for
targets of Yorkie transcription (Pan 2010).
Transcriptional targets of Yorkie include a number of
genes in Drosophila that are not conserved in higher
eukaryotes, implying that a substantial divergence in
transcriptional regulation of cell proliferation by this
pathway has occurred between species. However, given
that a common feature of cell cycle control by the RB and
Hippo pathways is transcriptional control, an important
question remains as to whether these pathways regulate
common or distinct targets in cell cycle regulation.
The convergence of Hippo and RB pathway
signaling in Drosophila melanogaster
Both the Hippo and RB pathways control proliferation,
and both have undeniable links to cancer. The ability of
these pathways to work together was first investigated in
the developing eye of the fruit fly, where it was discovered
that rbf and warts mutations synergize to create a deficiency in cell cycle exit during differentiation (Nicolay
et al. 2010). Nicolay et al. (2011) presented key evidence
that these pathways collaborate at a transcriptional level
in the February 15, 2011, issue of Genes & Development.
In this study, they used a DNA microarray approach to
identify common classes of target genes that are deregulated in response to rbf and warts mutations, alone or
in combination. This revealed some similarity in the patterns of gene expression that are changed by these mutants. Their data also revealed a significant increase in
cell cycle genes that are deregulated by both mutations in
combination, compared with either single mutation. Inspection of promoter sequences of these common target
genes revealed binding sites for both dE2F transcription
factors and Scalloped. Transcriptional reporter assays
further revealed a synergistic activation of these target
genes by dE2F1 and Yorkie/Scalloped. In addition, chromatin immunoprecipitation experiments showed that
dE2F1 and Scalloped occupy many common cell cycle

promoters in relatively close proximity. Nicolay et al.
(2011) also demonstrated that Yorkie-induced proliferation in the eye requires dE2F1, and that Rbf proteins can
contribute to the suppression of transcription and proliferation by Yorkie. Surprisingly, Yorkie-induced proliferation is suppressed by Rbf even in the absence of dE2F1.
This demonstrates that the RB and Hippo pathways not
only converge to regulate common genes, but also cooperate with and interregulate one another at these target
promoters (Fig. 2A).
The introductions for the RB and Hippo pathways above
highlight the extensive conservation of these molecular
mechanisms for transcriptional and growth control between organisms such as fruit flies and humans (Fig. 1).
Puzzlingly, the conservation of this mechanism ends with
transcriptional regulation by Yorkie and its mammalian
orthologs, YAP/TAZ. As explained by Nicolay et al. (2011),
the regulation of key cell cycle targets such as Cyclin E,
Cyclin A, and Cyclin B by Yorkie is not mirrored by
mammalian YAP/TAZ. This leaves in question how the
mammalian RB and Hippo pathways communicate. Conservation of the function of these pathways suggests they
will, but the available data lead to the conclusion that the
mechanism must be different in mammals compared with
Drosophila.
The interaction of the RB and Hippo pathways
in mammals
Two studies that appeared in the April 15, 2011, issue of
Genes & Development investigated the functions of RB
family proteins and discovered clear mechanisms of cooperation with the Hippo pathway in mammalian cell
cycle control (Litovchick et al. 2011; Tschöp et al. 2011).

Figure 2. Mechanisms of coordination between RB and Hippo
pathways in cell cycle control. The convergence of Hippo signaling on E2F transcription that was described in recent studies is
summarized. (A) A diagram of how Rbf regulates dE2F and Yki/Sd
cooperation at E2F target genes in growth-arrested cells. (B) The
signaling cascade from LATS to DYRK and p130–DREAM is
illustrated to explain how DREAM is assembled to silence E2F
target gene expression in growth-arrested cells.
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These reports offer a substantial advancement in our
broader understanding of cell proliferation by providing
mechanistic insight into cell cycle withdrawal.
In the study by Tschöp et al. (2011), the authors investigate the mechanism of pRB-dependent growth arrest. They take advantage of the sensitivity of RB1-null
human osteoblast-like osteosarcoma SaOS-2 cells to arrest
in response to pRB re-expression and perform an shRNA
screen for kinases that are required for pRB-dependent
proliferative control. In addition, they also screen for
kinases that are necessary for markers of senescence at
later stages of this pRB-dependent arrest. These screens
offer the generality that stress-responsive kinases are the
most commonly required companions of pRB in suppressing cell proliferation. Intriguingly, the senescence screen
showed a strong requirement for the mammalian Warts
kinase homolog LATS2, providing the first evidence in
mammalian cells that pRB-induced senescence is impacted by components of the Hippo pathway. Phenotypically, the LATS2 requirement in senescence is not
completely related to supporting pRB function per se.
Surprisingly, SaOS-2 cells arrest in G1 in response to
expression of exogenous pRB, regardless of whether LATS2
is depleted by shRNA. Despite this, it was noted that
LATS2 was required for complete repression of E2F target
genes by pRB. More importantly, the role for LATS2
appears to be critical in establishing downstream characteristics of senescent cells, including inducing senescence-associated b-galactosidase (SA-bGal) activity and
stimulating the formation of senescence-associated heterochromatic foci (SAHF). Tschöp et al. (2011) further
investigated the effect of LATS2 depletion on SAHF formation and SA-bGal expression in a number of different cell
systems and paradigms for senescence. Using these assays,
they came to the same conclusion: LATS2 is required for
many of the defining characteristics of senescence.
By mining expression microarray data sets, Tschöp
et al. (2011) discovered that LATS2 mRNA levels are inversely correlated with those of known E2F target genes.
Furthermore, depletion of LATS2 expression by shRNA
in senescence leads to elevated levels of E2F targets.
Given that YAP/TAZ are known to be the focus of Hippo
signaling, Tschöp et al. (2011) sought to investigate
whether they can regulate E2F target gene expression.
However, unlike the results published by Nicolay et al.
(2011) studying the fruit fly Rbf and Hippo pathways,
Tschöp et al. (2011) were unable to detect elevated E2F
target gene expression when YAP was ectopically expressed
in cells. Similarly, coexpression of YAP failed to enhance
E2F1-dependent activation of transcription. These data
suggest that LATS2 signaling has targets other than YAP/
TAZ that are required for silencing E2F target genes.
A logical candidate that represses E2F transcription
independently of pRB during senescence is the p130–
DREAM complex. To this end, Tschöp et al. (2011) used
chromatin immunoprecipitation experiments to investigate the occupancy of E2F target gene promoters by p130
and DREAM components. As expected p130, LIN9, and
LIN54 associate with E2F-responsive promoters in a pRBdependent manner. Furthermore, depletion of LATS2
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expression reduces the assembly of this complex at E2Fresponsive promoters in senescence. These experiments
elegantly demonstrate that the mammalian Hippo pathway contributes to E2F-regulated gene silencing in senescence. Given the past challenges in delineating independent roles for pRB and family members like p130, this
study reveals an intriguing separation of function whereby
pRB is the initial brake that allows for cell cycle exit. In
turn, the p130–DREAM complex is then enabled by
LATS2 to repress E2F-dependent transcription, which
leads to the characteristics of a fully senescent cell.
Regulation of p130–DREAM assembly in senescence
The discovery that the mammalian Hippo pathway can
regulate the activity of the p130–DREAM complex and,
subsequently, E2F-dependent transcription raises the obvious question of how this is accomplished on a mechanistic level. A study by Litovchick et al. (2011) that was
also published in the April 15, 2011, issue of Genes &
Development offers a very complete answer as to how assembly of the p130–DREAM complex is regulated and how
this impacts on cell cycle control to induce senescence.
This study is based on a proteomic analysis of p130-,
E2F4-, and Myb-containing complexes. In a previous
report, this approach revealed the composition of the
DREAM complex in humans (Litovchick et al. 2007). In
this new study, Litovchick et al. (2011) mined their data
set of peptides for phosphorylation sites on the constituent subunits of DREAM. By comparing the frequency of
phospho-peptide identification between each immunoprecipitation (performed with different antibodies against
individual components of the p130–DREAM complex
and Myb), they were able to identify phosphorylation of
LIN52 on Ser 28 as being an exclusive post-translational
modification to the DREAM complex when bound to
p130. Taking advantage of the slower migration in SDSPAGE induced by Ser 28 phosphorylation, Litovchick
et al. (2011) independently verified that p130 exclusively
bound DREAM containing phosphorylated LIN52. Furthermore, by depleting endogenous LIN52 and re-expressing a serine-to-alanine LIN52 mutant, they established
that phosphorylation of LIN52 is necessary and sufficient
to regulate DREAM binding to p130.
Given the elegant regulation of p130 and DREAM interactions by a single phosphorylation event, Litovchick
et al. (2011) then sought to identify the kinase responsible. To do this, they again referred to their mass spectrometry data and identified DYRK1A as a candidate that
copurifies with p130–DREAM. The DYRKs (dual-specificity tyrosine phosphorylation-regulated kinases) are
a family of kinases that autophosphorylate a tyrosine
residue in their activation loop and catalyze the phosphorylation of serine/threonine residues on numerous substrates (Becker and Joost 1999), including many transcription
factors. Members of this kinase family from lower eukaryotes are Yak1 in Saccharomyces cerevisiae, Pom1 in Schizosaccharomyces pombe, YakA in Dictyostelium, and minibrain in Drosophila. Although strains with mutations in
these proteins display different phenotypic abnormalities,
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all are involved in cell cycle regulation or in controlling the
transition from cell growth to differentiation (Tejedor and
Hammerle 2011). Mammalian DYRKs include DYRK1A,
DYRK1B, DYRK2, DYRK3, and DYRK4 (Becker and Joost
1999). DYRK1A is the most extensively characterized
member of this family, and it shares all of the characteristic
motifs of its catalytic domain with the other family
members. In humans, DYRK1A is located in the ‘‘Down
syndrome-critical region’’ on chromosome 21q22.2, and is
thought to play a role in the aberrant brain development,
early onset neurodegeneration, neuronal loss, and dementia associated with this disease (Tejedor and Hammerle
2011; Wegiel et al. 2011). The human and rodent DYRK1A
genes are ubiquitously expressed in tissues of adult and
fetal origin.
Litovchick et al. (2011) provide experimental evidence
that DYRK1A-dependent assembly of p130–DREAM is
required for serum starvation-induced exit from the cell
cycle and senescence. In addition, expression of a LIN52
S28A mutant interferes with entry into senescence and
SA-bGal expression. Taken together, this study provides
compelling evidence that DYRK1A is a novel regulator
of E2F target gene expression through its essential role
in controlling the assembly of p130–DREAM complexes.
Through phosphorylation of just one site on the DREAM
complex, it has a clear impact on growth arrest and
senescence.
DYRKs, potential components of the Hippo pathway
The Tschöp et al. (2011) study demonstrates a role for
p130–DREAM in pRB-induced senescence, and the
Litovchick et al. (2011) study reveals that assembly of
p130–DREAM requires phosphorylation by DYRK1A.
Together, they both demonstrate an essential role for
p130–DREAM in suppressing E2F target gene expression
during senescence. The linkage between these observations begins with the finding that members of the DYRK
family are essential for pRB-induced senescence in the
kinome screen performed by Tschöp et al. (2011). In
addition, DYRK1A contains putative consensus phosphorylation sites for the LATS2 kinase. This suggests a linear
pathway of assembly in which LATS is directly upstream
of DYRK1A. Using an in vitro kinase assay system, the
DeCaprio and Dyson groups (Tschöp et al. 2011) collaborated to demonstrate that LATS2 can indeed phosphorylate and activate DYRK1A, and this in turn stimulates its
ability to phosphorylate LIN52. These data suggest that
DYRK kinases may be new members of the Hippo signaling
pathway that link it to p130-dependent regulation of proliferation (Fig. 2B). Information regarding in vivo regulation
of DYRK activity in mammalian cells is scarce, and the
novel observation by Tschöp et al. (2011) that LATS2 can
directly phosphorylate DYRK1A and stimulate its activity
represents the first description of a cellular mechanism for
regulating DYRK1A beyond alterations in expression.
These experiments demonstrate how DYRK1A can
block proliferation through p130–DREAM. Is this activity fully duplicated by the paralogous DYRK1B kinase?
The Litovchick et al. (2011) study clearly demonstrates

that DYRK1B can also interact with and phosphorylate
LIN52 in vitro, but they were unable to demonstrate
a specific role for endogenous DYRK1B in vivo. Although
exogenous overexpression of DYRK1B was shown to
rescue the effect of depleting DYRK1A, it remains to be
determined whether this is physiologically relevant.
Should this turn out to be the case, control of DYRK1B
may be independent of LATS2, as the putative consensus
phosphorylation site for this kinase is not present in
DYRK1B.
Activation of DYRK1A by LATS2 presumably leads to
phosphorylation of other targets beyond LIN52 Ser 28.
Are these substrates solely confined to regulating cell
proliferation? Given that altered DYRK1A dosage has
effects on neuronal differentiation, placing it downstream
from HIPPO—a regulator of neural progenitor cell number (Cao et al. 2008)—may suggest a broader function for
this kinase signaling cascade.
DYRK1A and DYRK1B are currently considered to be
prosurvival kinases (Aranda et al. 2011). Each has been
reported to be expressed at elevated levels in multiple
cancer types and to inhibit apoptosis through a variety of
direct or indirect mechanisms. Given that DYRK1A, and
potentially DYRK1B, promotes cell cycle arrest via p130–
DREAM, this concept may require further investigation.
In some instances, high levels of these DYRKs could
confer a selective survival advantage to tumor cells by
enhancing their ability to attain quiescence during unfavorable growth conditions, which might be interpreted
as inhibition of apoptosis. In other instances, high level
expression of these DYRKs may not actually have any
functional consequence, but may merely reflect a futile
attempt to regain control of the cell cycle in cells with
a nonfunctional RB pathway, akin to that observed for
p16 expression in cells deficient for pRB (von Knebel
Doeberitz 2001).
Final thoughts
In conclusion, these three studies collectively offer exciting insight into the coordination of proliferation through
two key cell cycle regulatory pathways. They demonstrate the convergence of signaling between the Hippo
and RB pathways at the level of transcriptional control.
They also reveal important details of the mechanisms in
fruit flies and mammals that allow these pathways to
communicate. This work also raises important new questions about signaling by the Hippo pathway in growth
arrest and, potentially, other paradigms such as differentiation, stress response, cell survival, and cancer.
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